Cardiorenal Effects of Long‐Term Phosphodiesterase V Inhibition in Pre–Heart Failure

Autor: Scott A. Hubers, Siu‐Hin Wan, Fadi W. Adel, Sherry L. Benike, John C. Burnett, Christopher Scott, Horng H. Chen

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 2 (2022)

Background Phosphodiesterase V (PDEV) is upregulated in heart failure, leading to increased degradation of cGMP and impaired natriuresis. PDEV inhibition improves the renal response to B‐type natriuretic peptide in animal models. We tested the hypo

Externí odkaz: https://doaj.org/article/4ff4a56f6ebf43bebf386f316d8a32d9

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin‐Deficient Hearts

Autor: David W. Hammers, Margaret M. Sleeper, Sean C. Forbes, Ai Shima, Glenn A. Walter, H. Lee Sweeney

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 8 (2016)

BackgroundCardiomyopathy is a leading cause of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic pathology, and the phosphodiesterase type 5 inhibitor tadalafil ha

Externí odkaz: https://doaj.org/article/db57d47aba7d4e3eacc7551b433ca575

Phosphodiesterase type 5 inhibition may reduce diastolic function in women with ischemia but no obstructive coronary artery disease

Autor: Daniel S. Berman, Debiao Li, Michael D. Nelson, Janet Wei, Behzad Sharif, Puja K. Mehta, C. Noel Bairey Merz, Louise Thomson

Publikováno v: Journal of Medical Case Reports, Vol 11, Iss 1, Pp 1-4 (2017)
Journal of medical case reports, vol 11, iss 1
Journal of Medical Case Reports

Background Ischemia, in the absence of obstructive coronary artery disease, is prevalent in women, and associated with increased risk for major cardiovascular events. Coronary microvascular dysfunction is prevalent in these patients, and associated w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd7ca93fad625454df05efbea16ad0de
http://link.springer.com/article/10.1186/s13256-017-1307-2

Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts

Autor: Margaret M. Sleeper, Ai Shima, H. Lee Sweeney, Sean C. Forbes, David W. Hammers, Glenn A. Walter

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

Background Cardiomyopathy is a leading cause of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic pathology, and the phosphodiesterase type 5 inhibitor tadalafil h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba4fc47aaaca04e5a68154d897f0f516
https://pubmed.ncbi.nlm.nih.gov/27506543

Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men

Autor: Simon Maxwell, David J. Webb, Lorenzo Malatino, Teresa M. Attina, Iain D. Drummond

Publikováno v: American journal of hypertension. 26(3)

BACKGROUND: Established hypertension is associated with abnormal exercise hemodynamics and reduced exercise capacity through mechanisms that may include contributions from arterial stiffness and endothelial vasomotor dysfunction. Phosphodiesterase ty

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84d1e41124e7d264f283b1f8e9063af3
https://pubmed.ncbi.nlm.nih.gov/23382484